Skip to main content

Press

Call for Applications: Editor-in-Chief of Neuro-Oncology Pediatrics


Apply Today!

Deadline: Tuesday, October 1, 2024

The Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) are pleased to announce the launch of Neuro-Oncology Pediatrics, which will be the fourth title in the Neuro-Oncology family of journals. This new peer-reviewed publication is dedicated to advancing the care, research, and treatment of children and adolescents with brain and spinal cord tumors.

About the Editor-in-Chief Position
Applications for the inaugural Editor-in-Chief of Neuro-Oncology Pediatrics are now being accepted. The ideal candidate will have a strong background in pediatric neuro-oncology, an outstanding track record of research in pediatric neuro-oncology, a strong record in publication, and the ability to lead a collaborative and inclusive editorial team. For the full position description and to apply, click here. 

About the New Journal
Neuro-Oncology Pediatrics joins SNO's family of journals, which includes Neuro-Oncology, Neuro-Oncology Advances, and Neuro-Oncology Practice, all published in partnership with Oxford University Press. Like Neuro-Oncology Advances, the new journal is a fully open-access title, ensuring that the global pediatric neuro-oncology community can benefit from the rapidly developing research and science from the field with the necessity of a subscription.

Neuro-Oncology Pediatrics aims to be the primary platform for publishing rigorous, peer-reviewed research studies, including clinical trials, basic science and translational research that advance the understanding and treatment of pediatric brain and spinal cord tumors.

The Society for Neuro-Oncology is grateful to the Pediatric Brain Tumor Foundation for their vision and generous financial support to help launch the journal. Their investment in this endeavor will have a lasting impact on the pediatric neuro-oncology community, driving forward innovations and breakthroughs that will benefit patients worldwide.